Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04025372 · ClinicalTrials.gov registry record · Phase 2
INTREPId (INTermediate Risk Erection PreservatIon Trial)
A Phase 2 study of Prostate Cancer, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
- 11
- Study locations
NCT04025372 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 234 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 11 study locations across 5 states.
The verdict
NCT04025372, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
- 11
- Study locations
Study Summary
This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.
Conditions Studied
Interventions
- DRUG Darolutamide
- RADIATION Radiation Therapy
- DRUG Bicalutamide
- DRUG GnRH Agonist
Study Locations (11)
Massachusetts
- Beth Israel Deaconness Medical Center - Boston
- Brigham and Women Hospital - Boston
- Dana Farber Cancer Institute - Boston
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center - Milford
- Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital - South Weymouth
New York
- NYU Long Island - Garden City
- NYU Langone Health - New York
- Associated Medical Professionals of NY - Syracuse
Connecticut
- Stamford Hospital - Stamford
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Nebraska
- XCancer Omaha / Urology Cancer Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04025372
The ClinicalTrials.gov registry entry for NCT04025372 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Darolutamide is the first listed.
NCT04025372 reports 11 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, New York, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04025372 about?
NCT04025372 is a clinical study titled "INTREPId (INTermediate Risk Erection PreservatIon Trial)". This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therap...
What is the current status of trial NCT04025372?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2020-06-01. Estimated completion is 2028-03-01.
What conditions does trial NCT04025372 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04025372?
The interventions under investigation include: Darolutamide (DRUG), Radiation Therapy (RADIATION), Bicalutamide (DRUG), GnRH Agonist (DRUG).
Who is sponsoring clinical trial NCT04025372?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04025372 being conducted?
This trial has 11 study locations across Connecticut, Massachusetts, Missouri, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.